Activation of ribosomal protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal growth factor receptor ligands

Journal of Investigative Dermatology

Volumn 108, Issue 1, 1997, Pages 98-102

  Choi, Jee Ho ^a   O'Connor, Timothy P ^a,c   Kang, Sewon ^a   Voorhees, John J ^a   Fisher, Gary J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Psoriasis; Rapamycin; Transforming growth factor

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; PROTEIN KINASE; RAPAMYCIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS;

EID: 0031016138     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12285647     Document Type: Article

References (39)

1. Amagi M, Ozawa S, Ueda M, Nishikawa T, Abu O, Shimizu N: Distribution of EGF receptor expressing and DNA replicating epidermal cells in psoriasis vulgaris and Bowen's disease. Br J Dermatol 119:661-668, 1988
2. Babich H, Borenfreund H: Structure-activity relationship (SAR) models established in vitro with the neutral red cytotoxicity assay. Toxicology in Vitro 1:3-9, 1987
3. Ballou LM, Luther H, Thomas G: MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature 349:348-349, 1991
4. Ballou LM, Siegmann M, Thomas G: S6 kinase in quiescent Swiss mouse 3T3 cells is activated by phosphorylation in response to serum treatment. Proc Natl Acad Sci USA 85:7154-7158, 1988
5. Beirer BE, Mattila PS, Standaert RF, Herzenberg IA, Burakoff SJ, Carbtree G, Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 87:9231-9235, 1990
6. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 239:756-758, 1994
7. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL: Control of p70 S6 kinase by kinase activity of FRAP in vivo. Science 377:441-446, 1995
8. Chung JK, Kuo CJ, R CG, Blenis J: Rapamycin-FKBP specially blocks growth-dependent activation of and signaling by the 70kd S6 protein kinase. Cell 69:1227-1236, 1992
9. Cook P, Pittelkow M, Keeble W, Graves-Deal R, Coffey RJ, Shipley G: Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 52:3224-3227, 1992
10. Downwand J: Regulating S6 kinase. Nature 371:378-379, 1994
11. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144:251-258, 1990
12. Duncan JI: Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK506, and rapamycin. J Invest Dermatol 102:84-88, 1994
13. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey Jr RJ, Ellingsworth L, Derynck R, Voorhees JJ: Overexpression of transforming growth factor α in psoriatic epidermis. Science 243:811-814, 1989
14. Elder JT, Klein SB, Tavakkol A, Fisher GJ, Nickoloff BJ, Voorhees JJ: Growth factor and proto-oncogene expression in psoriasis. J Invest Dermatol 95:7S-9S, 1990a
15. Elder JT, Tavakkol A, Klein SB, Zeigler ME, Wicha M, Voorhees JJ: Protooncogene expression in normal and psoriatic skin. J Invest Dermatol 94:18-25, 1990b
16. S6K through dephosphorylation of a novel set of sites. J Biol Chem 268:16091-16094, 1993
17. Ferrari S, Thomas G: S6 phosphorylation and the p70S6K/p85S6K. Crit Rev Biochem Mol Biol 29:385-413, 1994
18. Fisher GJ, Esmann J, Griffiths CEM, Talwar HS, Duell EA, Hammerberg C, Elder JT, Karabin GD, Nickeloff BJ, Cooper KD, Voorhees JJ: Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin. J Invest Dermatol 96:688-707, 1991
19. Fry D, Kraker A, McMicheal A, Ambroso L, Nelson L, Leopold W, Connors R, Bridges A: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093-1095, 1994
20. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:9115-909, 1991
21. King Jr LE, Gates RE, Stescheck CM, Nanncy LB: The EGF/TGFα receptor in skin. J Invest Dermatol 94:164S-170S, 1990
22. Krueger JG, Krane JF, Carter DM, Gottlieb AB: Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 94:135S-140S, 1990
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227:680-685, 1970
24. S6K function is essential for G1 progression. Nature 363:170-172, 1993
25. ras. Nature 371:426-429, 1994
26. 125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 86:260-265, 1986
27. Olaniran AK, Baker BS, Garioch JJ, Powles AV, Fry L: A comparison of the stimulatory effects of cytokines on normal and psoriatic keratinocytes in vitro. Arch Dermatol Res 287:231-236, 1995
28. Pittelkow MR, Scott RE: New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns. Mayo Clin Proc 61:771-777, 1986
29. Price D, Grove J, Calvo V, Avruch J, Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257:973-977, 1992
30. Quesniaux VFJ: Immunosuppressants: tools to investigate the physiological role of cytokines. BioEssays 15:731-758, 1993
31. Reynolds N, Baldassare J, Henderson P, Shuler J, Ballas L, Burns D, Moomaw C, Fisher G: Translocation and down regulation of protein kinase C isoenzymes-alpha and epsilon by phorbol ester and bryostatin-1 in human keratinocytes and fibroblasts. J Invest Dermatol 103:364-369, 1994
32. Sabatini DM, Erdjumnet-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: a mammalian protein that hinds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43, 1994
33. Schreiber AB, Winkler ME, Derynck R: Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253, 1986
34. Schreier MH, Baumann G, Zenke G: Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? Transplant Proc 25:502-507, 1993
35. Schrieber S: Immunophillin-sensitive protein phosphatase action in cell signaling pathways. Cell 70:365-368, 1992
36. Shipley GD, Pittelkovv MR: Control of growth and differentiation in vitro of human keratinocytes cultured in serum-free medium. Arch Dermatol 123:1541a-1544a, 1987
37. Stewart MJ, Thomas G: Mitogenesis and protein synthesis: a role tor ribosomal protein S6 phosphorylation. BioEssays 16:809-815, 1994
38. Terada N, Franklin RA, Lucas JJ, Blenis J, Gelfand EW: Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem 208:12062-12068, 1993
39. Thomson AW, Starzl TF: New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 136:71-98, 1993